药物转运体OCTN1基因启动子区SNP rs460089对接受伊马替尼治疗的慢性髓性白血病患者无治疗缓解的预后价值
本研究基于EURO-SKI试验和波兰STOP伊马替尼研究,探讨SLC22A4基因启动子区SNP rs460089与慢性髓性白血病患者无治疗缓解(TFR)持续性的关联。学习样本176例中,rs460089-GC基因型患者6个月无分子复发生存(MRFS)概率显著高于GG基因型(73% vs 51%),随时间GC型MRFS概率亦显著更高(HR 0.474)。波兰研究93例验证了上述结果。多因素回归中,除基因型外,TKI治疗时长(EURO-SKI)和深度分子学缓解时长(波兰研究)为独立预后因素。rs460089被确定为TFR的独立预测因子。
要点
- rs460089-GC型患者6个月MRFS概率73%(95%CI 60-82%),显著高于GG型的51%(95%CI 41-61%)。
- GC型患者随时间MRFS概率显著高于GG型(HR 0.474,95%CI 0.280-0.802,p=0.0054)。
- 波兰STOP伊马替尼研究93例验证了上述关联,rs460089为TFR独立预测因子。
核心结论
- SNP rs460089是接受伊马替尼治疗的慢性髓性白血病患者TFR的独立预测因子。
研究设计与样本
- 研究基于EURO-SKI试验学习样本176例患者,并在波兰STOP伊马替尼研究93例患者中验证。
- 研究分析rs460089药物遗传型与TFR持续性的关联。
主要发现
- 学习样本中,GC型患者6个月MRFS概率73%(95%CI 60-82%),GG型51%(95%CI 41-61%),GC型显著更高。
- 随时间GC型MRFS概率显著高于GG型(HR 0.474,95%CI 0.280-0.802,p=0.0054)。
- 上述结果在波兰STOP伊马替尼研究93例患者中得到验证。
- 多因素回归中,除基因型外,TKI治疗时长(EURO-SKI试验)和深度分子学缓解时长(波兰研究)为独立预后因素。
关键数值与推荐
- 学习样本176例:GC型6个月MRFS概率73%(95%CI 60-82%),GG型51%(95%CI 41-61%)。
- 随时间MRFS比较:GC型 vs GG型 HR 0.474(95%CI 0.280-0.802,p=0.0054)。
- 验证样本93例来自波兰STOP伊马替尼研究。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect allele arrangement of genes encoding drug transporters associated with treatment response. In previous work, we identified SNP rs460089 located in the promotor of SLC22A4 gene encoding imatinib transporter OCTN1 as influential on response of patients with chronic myeloid leukemia treated with imatinib. Patients with rs460089-GC pharmacogenotype had significantly superior response to first-line imatinib treatment compared to patients with rs460089-GG. This study investigated whether pharmacogenotypes of rs460089 are associated with sustainability of treatment-free remission (TFR) in patients from the EUROpean Stop Kinase Inhibitor (EURO-SKI) trial. In the learning sample, 176 patients showed a significantly higher 6-month probability of molecular relapse free survival (MRFS) in patients with GC genotype (73%, 95% CI: 60-82%) compared to patients with GG (51%, 95% CI: 41-61%). Also over time, patients with GC genotype had significantly higher MRFS probabilities compared with patients with GG (HR: 0.474, 95% CI: 0.280-0.802, p = 0.0054). Both results were validated with data on 93 patients from the Polish STOP imatinib study. In multiple regression models, in addition to the investigated genotype, duration of TKI therapy (EURO-SKI trial) and duration of deep molecular response (Polish study) were identified as independent prognostic factors. The SNP rs460089 was found as an independent predictor of TFR.
引用
- Machova Polakova K, Albeer A, Polivkova V, et al. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia. 2023. PMID: 38129513. doi:10.1038/s41375-023-02109-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。